Current Report Filing (8-k)
30 October 2019 - 11:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 30, 2019
BIOSTAGE, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-35853
|
45-5210462
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
84 October Hill Road, Suite 11, Holliston, MA
|
01746
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code: (774) 233-7300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
On October 30, 2019, Biostage, Inc. (the
“Company”) issued a press release announcing that the Company has submitted an Investigational
New Drug, or IND, application to the U.S. Food and Drug Administration for the Company’s lead product candidate, the Cellspan
Esophageal Implant. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
The Company hereby files the following exhibit:
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
BIOSTAGE, INC.
|
|
|
(Registrant)
|
|
|
|
October 30, 2019
|
|
/s/ James McGorry
|
(Date)
|
|
James McGorry
Chief Executive Officer
|
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Apr 2024 to May 2024
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From May 2023 to May 2024